MS-forbundet (04.03.2022)

Risikoen kan tones ned

 

JAMA Neurology (24.01.2022)

Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination

 

Journal of Neurology, Neurosurgery and Psychiatry (20.10.2021)

Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations

 

medrXiv: the preprint server of health sciences (18.10.2021)

Efficacy and safety of a third SARS-CoV-2 vaccination in multiple sclerosis vaccine non-responders

 

Dagens Medisin (03.08.2021)

Har samlet inn over 1900 blodprøver til vaksinestudie for MS-pasienter

 

Dagens Medisin (27.01.2022)

25 prosent i Nevrovax-studien hadde effekt av tredje dose

 

MS-rapporten (19.11.2021, s. 25)

Enorm interesse for vaksinestudie